Mediated Drug Release from Nanovehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease

Angew Chem Int Ed Engl. 2020 Nov 9;59(46):20568-20576. doi: 10.1002/anie.202008379. Epub 2020 Sep 3.

Abstract

Chronic obstructive pulmonary disease (COPD) is an intractable disease involving a sticky mucus layer and nanoagents with mucus-penetrating capability offer a new way to deliver drugs. However, drug release from nanovehicles requires optimization to enhance the therapeutic effects of COPD therapy. Herein, black phosphorus quantum dots (BPQDs) are combined with PEGylated chitosan nanospheres containing the antibiotic amikacin (termed PEG@CS/BPQDs-AM NPs). As a drug-delivery system, the hydrophilicity of PEG and positive charge of CS facilitate the penetration of nanovehicles through the mucus layer. The nanovehicles then adhere to the mucous membrane. Furthermore, the BPQDs degrade rapidly into nontoxic PO43- and acidic H+ , thereby promoting the dissociation of PEGylated CS nanospheres, accelerating the release of AM, decreasing the vitality of biofilms for ease of eradication. Our results reveal that drug delivery mediated by BPQDs is a feasible and desirable strategy for precision medicine and promising for the clinical therapy of COPD.

Keywords: 2D materials; black phosphorus; chronic obstructive pulmonary disease; nanoparticles; quantum dots.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Drug Carriers*
  • Drug Liberation
  • Humans
  • Mice
  • Mucus / drug effects
  • Nanoparticles*
  • Phosphorus / chemistry*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Quantum Dots / chemistry*

Substances

  • Anti-Bacterial Agents
  • Drug Carriers
  • Phosphorus